<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23843932</article-id><article-id pub-id-type="pmc">3701078</article-id><article-id pub-id-type="publisher-id">PONE-D-12-28419</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0062873</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Computer Science</subject><subj-group><subject>Computer Applications</subject><subj-group><subject>Web-Based Applications</subject></subj-group></subj-group><subj-group><subject>Information Technology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Mental Health</subject><subj-group><subject>Psychiatry</subject><subj-group><subject>Anxiety Disorders</subject><subject>Mood Disorders</subject></subj-group></subj-group><subj-group><subject>Therapies</subject><subj-group><subject>Psychotherapy</subject></subj-group></subj-group></subj-group><subj-group><subject>Non-Clinical Medicine</subject><subj-group><subject>Health Informatics</subject></subj-group></subj-group><subj-group><subject>Public Health</subject><subj-group><subject>Behavioral and Social Aspects of Health</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Social and Behavioral Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Behavior</subject><subj-group><subject>Emotions</subject></subj-group></subj-group><subj-group><subject>Therapies</subject><subj-group><subject>Psychotherapy</subject></subj-group></subj-group><subj-group><subject>Clinical Psychology</subject><subject>Psychological Stress</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Improving Adherence and Clinical Outcomes in Self-Guided Internet Treatment for Anxiety and Depression: Randomised Controlled Trial</article-title><alt-title alt-title-type="running-head">Improving Self-Guided Internet Treatments</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Titov</surname><given-names>Nickolai</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dear</surname><given-names>Blake F.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>Luke</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lorian</surname><given-names>Carolyn</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Judy</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wootton</surname><given-names>Bethany</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Spence</surname><given-names>Jay</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McEvoy</surname><given-names>Peter M.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rapee</surname><given-names>Ronald M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Specialist Clinical Psychologist, Centre for Clinical Interventions and School of Psychology, University of Western Australia, Perth, Australia</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Andersson</surname><given-names>Gerhard</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Linkoping University, Sweden</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>nick.titov@mq.edu.au</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>NT and BFD are authors and developers of the Wellbeing Course, but derive no personal or financial benefit from it. NT, BFD, and RR have developed and operate a national telephone and online treatment service, the MindSpot Clinic (<ext-link ext-link-type="uri" xlink:href="http://www.mindspot.org.au">www.mindspot.org.au</ext-link>), for people with anxiety and depression, funded by the Australian Government. This service uses a version of the Wellbeing treatment course.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: NT BFD LJ CL JZ BW JS PM RR. Performed the experiments: NT BFD LJ CL JZ BW. Analyzed the data: NT BFD LJ. Wrote the paper: NT BFD LJ CL JZ BW JS PM RR.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>3</day><month>7</month><year>2013</year></pub-date><volume>8</volume><issue>7</issue><elocation-id>e62873</elocation-id><history><date date-type="received"><day>7</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Titov et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Titov et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Depression and anxiety are common, disabling and chronic. Self-guided internet-delivered treatments are popular, but few people complete them. New strategies are required to realise their potential.</p></sec><sec><title>Aims</title><p>To evaluate the effect of automated emails on the effectiveness, safety, and acceptability of a new automated transdiagnostic self-guided internet-delivered treatment, the Wellbeing Course, for people with depression and anxiety.</p></sec><sec><title>Method</title><p>A randomised controlled trial was conducted through the website: <ext-link ext-link-type="uri" xlink:href="http://www.ecentreclinic.org">www.ecentreclinic.org</ext-link>. Two hundred and fifty seven people with elevated symptoms were randomly allocated to the 8 week course either with or without automated emails, or to a waitlist control group. Primary outcome measures were the Patient Health Questionnaire 9-Item (PHQ-9) and the Generalized Anxiety Disorder 7-Item (GAD-7).</p></sec><sec><title>Results</title><p>Participants in the treatment groups had lower PHQ-9 and GAD-7 scores at post-treatment than controls. Automated emails increased rates of course completion (58% vs. 35%), and improved outcomes in a subsample with elevated symptoms.</p></sec><sec><title>Conclusions</title><p>The new self-guided course was beneficial, and automated emails facilitated outcomes. Further attention to strategies that facilitate adherence, learning, and safety will help realise the potential of self-guided interventions.</p></sec><sec><title>Trial Registration</title><p>
<ext-link ext-link-type="uri" xlink:href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336276">Australian and New Zealand Clinical Trials Registry ACTRN12610001058066</ext-link>
</p></sec></abstract><funding-group><funding-statement>This research was enabled by funding from the Australian National Health and Medical Research Council Project Grant No. #630560. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The World Mental Health Surveys indicate that globally more than 500 million people each year meet diagnostic criteria for anxiety and depressive disorders <xref rid="pone.0062873-Kessler1" ref-type="bibr">[1]</xref>. Effective psychological treatments for these conditions are increasingly available via the internet (internet psychotherapy; iPT), which offers improved accessibility and convenience for both patients and clinicians <xref rid="pone.0062873-Titov1" ref-type="bibr">[2]</xref>.</p><p>Disorder-specific iPT interventions are clinically effective for adults with anxiety disorders and depression when guided by a therapist <xref rid="pone.0062873-Andersson1" ref-type="bibr">[3]</xref>, <xref rid="pone.0062873-Andrews1" ref-type="bibr">[4]</xref>, <xref rid="pone.0062873-Cuijpers1" ref-type="bibr">[5]</xref>, <xref rid="pone.0062873-Lewis1" ref-type="bibr">[6]</xref>. Recent work indicates that transdiagnostic iPT interventions, which treat symptoms of both anxiety and depression in the same intervention, are also efficacious when administered by a therapist <xref rid="pone.0062873-Johnston1" ref-type="bibr">[7]</xref>, <xref rid="pone.0062873-Dear1" ref-type="bibr">[8]</xref>, <xref rid="pone.0062873-Titov2" ref-type="bibr">[9]</xref>. However, many consumers prefer and opt for self-guided iPT over therapist-guided versions. For example, recent research by a large iPT clinic found that only 75 of 2660 (i.e., 2%) consecutive participants elected for therapist-guided iPT over self-guided iPT <xref rid="pone.0062873-Klein1" ref-type="bibr">[10]</xref>.</p><p>Publicly available self-guided iPT interventions are popular. For example, the Panic Center (<ext-link ext-link-type="uri" xlink:href="http://www.paniccentre.net">www.paniccentre.net</ext-link>) and Moodgym (<ext-link ext-link-type="uri" xlink:href="http://www.moodgym.anu.edu.au">www.moodgym.anu.edu.au</ext-link>), which offer disorder-specific and self-guided online interventions, each have more than 400,000 registered users. Unfortunately, while data indicate that those who adhere and complete these interventions obtain good outcomes <xref rid="pone.0062873-Cavanagh1" ref-type="bibr">[11]</xref>, <xref rid="pone.0062873-Christensen1" ref-type="bibr">[12]</xref>, <xref rid="pone.0062873-Farvolden1" ref-type="bibr">[13]</xref>, the full public health potential of self-guided iPT has arguably not yet been realised. Typically more than 90% of consumers withdraw after two sessions and, thus, are unlikely to receive a &#x02018;dose&#x02019; of therapeutic content sufficient to lead to sustained improvement. Self-guided transdiagnostic iPT interventions which include strategies that facilitate adherence have considerable potential for greater outcomes while providing clinically and cost effective treatment to large numbers of people.</p><p>One strategy for improving adherence is to utilise reminders that promote both exposure to therapeutic content and practice of therapeutic skills <xref rid="pone.0062873-vanDulmen1" ref-type="bibr">[14]</xref>. Surprisingly, very few self-guided iPT interventions provide reminders. However, a trial of self-guided iPT for depression <xref rid="pone.0062873-Clarke1" ref-type="bibr">[15]</xref> demonstrated that reminders increased clinical symptom reductions relative to an earlier trial without reminders <xref rid="pone.0062873-Clarke2" ref-type="bibr">[16]</xref> and evidence that effect was more pronounced in participants who were more severely depressed at pre-treatment. Similarly, comparisons across trials of iPT for adults with social phobia show that automated reminder emails increased completion rates and effect sizes relative to earlier trials without automated reminders <xref rid="pone.0062873-Titov3" ref-type="bibr">[17]</xref>, <xref rid="pone.0062873-Titov4" ref-type="bibr">[18]</xref>, <xref rid="pone.0062873-Titov5" ref-type="bibr">[19]</xref>. Automated emails may be particularly suitable as a medium for providing reminders given the extremely low cost of emails and their ubiquity. Moreover, emerging studies are also indicating that emails can be used as a stand-alone self-help measure with sub-threshold depression to produce small but significant changes in symptom levels <xref rid="pone.0062873-Morgan1" ref-type="bibr">[20]</xref>. However, despite this emerging evidence and their potential, no studies have directly or systematically explored the ability of automated reminders in self-guided iPT to improve adherence and clinical outcomes.</p><p>The primary aim of the current study was to determine whether automated emails improved adherence and clinical outcomes during a new transdiagnostic self-guided iPT intervention, the <italic>Wellbeing Course</italic>, designed to treat symptoms of depression and anxiety. A secondary aim of the current study was to provide preliminary data about participant safety and the acceptability of the intervention. The study design simulated an automated and publically available website, where consumers applied and completed the intervention with no contact with staff. It was hypothesized that (1) automated emails would enhance completion rates and reductions on clinical symptoms, and (2) automated emails would be particularly beneficial for participants with elevated symptoms. No hypotheses were developed with respect to the acceptability or safety of the Wellbeing Course.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0062873.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0062873.s002">Protocol S1</xref>.</p><sec id="s2a"><title>Ethics Statement and Trial Registration</title><p>The study was approved by the Human Research Ethics Committee (HREC) of the University of New South Wales (UNSW, Sydney, Australia) and ratified by the Macquarie University HREC (Sydney, Australia; HREC Reference: 5201100226). The original protocol included telephone interviews at recruitment and a fourth group who received weekly contact with a therapist. However, in order to focus on the benefits of providing automatic emails during self-guided treatment and to simulate an entirely automated treatment process, the interviews and this fourth group were omitted from the final design. This change was approved by the UNSW HREC. The trial is registered with the Australian and New Zealand Clinical Trials registry as ACTRN12610001058066 and complies with updated CONSORT recommendations <xref rid="pone.0062873-Schulz1" ref-type="bibr">[21]</xref>.</p></sec><sec id="s2b"><title>Design and Sample Size</title><p>Eligible applicants were randomly allocated to one of two treatment groups or to a waitlist-deferred treatment control group. Participants in the Treatment Plus Automated Email Group (TEG; n&#x0200a;=&#x0200a;100) received access to the Wellbeing Course with automated emails. Participants in the Treatment Group (TG; n&#x0200a;=&#x0200a;106) received access to the Wellbeing Course without automated emails. The Control Group (Control; n&#x0200a;=&#x0200a;51) received access to the same treatment as the TEG group following post-treatment.</p><p>A weighted randomisation procedure was employed in which 40% of successful applicants were assigned to each treatment group and 20% were assigned to the control group. A priori power analysis indicated that 246 participants would be sufficient to detect a between-treatment group (Cohen&#x02019;s <italic>d</italic>) effect size (ES) difference &#x02265;0.35 between the two treatment groups and an ES difference &#x02265;0.55 between the treatment and control groups with alpha at.05 (one-tailed) and power of.80). These ESs were deemed sufficient, based on similar studies <xref rid="pone.0062873-Titov6" ref-type="bibr">[22]</xref>, <xref rid="pone.0062873-Robinson1" ref-type="bibr">[23]</xref> but more were recruited to hedge against attrition.</p><p>A colleague in another country used the website <ext-link ext-link-type="uri" xlink:href="http://www.random.org">www.random.org</ext-link> to create a list of 300 randomly generated numbers. These were numbers were sorted by size and the highest 20% and lowest 40% were marked to indicated they referred to the control group and the TG, respectively. The remainder were marked to indicate they belong to the TEG. The list was then returned to its original order and was used to automatically assign applicants to a condition.</p></sec><sec id="s2c"><title>Participants and Recruitment</title><p>Participants were automatically recruited from visitors to a research website that evaluates internet-delivered treatments (<ext-link ext-link-type="uri" xlink:href="http://www.ecentreclinic.org">www.ecentreclinic.org</ext-link>). After reading about the study and providing informed consent, applicants completed online questionnaires enquiring about symptoms of mood and anxiety, demographic details and treatment history.</p><p>During the seven weeks of recruitment in mid-2011, 381 individuals applied for this trial, and 274 met the following inclusion criteria: (i) Resident of Australia and at least 18 years of age; (ii) self-identified as having a principal complaint of depression, generalised anxiety disorder (GAD), social phobia, or panic disorder as indicated by total scores on at least one of the following measures: Patient Health Questionnaire-9 Item (PHQ-9) &#x0003e;9; <xref rid="pone.0062873-Kroenke1" ref-type="bibr">[24]</xref>, <xref rid="pone.0062873-Kroenke2" ref-type="bibr">[25]</xref> Generalised Anxiety Disorder-7 Item (GAD-7) &#x0003e;7; <xref rid="pone.0062873-Lwe1" ref-type="bibr">[26]</xref>, <xref rid="pone.0062873-Kroenke3" ref-type="bibr">[27]</xref> MINI Social Phobia Inventory (MINI-SPIN) &#x0003e;5; <xref rid="pone.0062873-SeeleyWait1" ref-type="bibr">[28]</xref> Autonomic Nervous System Questionnaire (ANSQ) &#x0003e;1, <xref rid="pone.0062873-Stein1" ref-type="bibr">[29]</xref> indicating likely diagnoses of depression, GAD, social phobia, and panic disorder, respectively; (iii) not currently participating in cognitive behavior therapy (CBT); (iv) no change in medications in the period 1 month prior to this study; (v) not currently experiencing a psychotic mental illness or severe symptoms of depression (defined as a total score &#x02265;23 or responding &#x0003e;2 to Question 9 (suicidal ideation) on the PHQ-9; (vi) had reliable Internet access; (vii) provided personal contact details.</p></sec><sec id="s2d"><title>Measures</title><p>The GAD-7, PHQ-9, MINI-SPIN and ANSQ were employed in the present trial as preliminary measures ensure participants had clinical level symptoms and were eligible for the trial. These measures are all widely used and all how high levels of sensitivity (i.e., &#x02265;.75) and specificity (i.e., &#x02265;.75), except the ANSQ which shows high levels of sensitivity (range:.94 to 1.00) but low levels of specificity (Range:.25 to.59) <xref rid="pone.0062873-Kroenke1" ref-type="bibr">[24]</xref>&#x02013;<xref rid="pone.0062873-Stein1" ref-type="bibr">[29]</xref>.</p><p>The primary outcome measures were severity of symptoms of depression and anxiety, measured by the PHQ-9 and GAD-7, which are based on the DSM-IV diagnostic criteria for depression and GAD, respectively. The GAD-7 has good convergent validity with other anxiety scales <xref rid="pone.0062873-Kroenke2" ref-type="bibr">[25]</xref>, is sensitive to DSM-IV congruent GAD, social phobia, and panic disorder, with increasing scores indicating greater symptom severity <xref rid="pone.0062873-Kroenke3" ref-type="bibr">[27]</xref>. The GAD-7 is increasingly used in research and in large scale dissemination studies as a generic measure of change in anxiety symptoms <xref rid="pone.0062873-Clark1" ref-type="bibr">[30]</xref>, <xref rid="pone.0062873-Richards1" ref-type="bibr">[31]</xref>. A total score of 10 on the PHQ-9 has been identified as an important threshold for identifying DSM-IV congruent depression with increasing scores indicating greater symptom severity, while psychometric studies indicate the measure is sensitive to change <xref rid="pone.0062873-Kroenke1" ref-type="bibr">[24]</xref>, <xref rid="pone.0062873-Kroenke2" ref-type="bibr">[25]</xref>, <xref rid="pone.0062873-Gilbody1" ref-type="bibr">[32]</xref>.</p><p>Secondary outcome measures included treatment satisfaction and completion rates (i.e., percentage in each treatment group who read the five online lessons of the Wellbeing Course within the 8 weeks of the course). Additional measures included changes in health status and service utilisation, which will be reported elsewhere.</p><p>TEG and TG participants completed the PHQ-9 and GAD-7 at pre-treatment, prior to each of the five lessons of the Wellbeing Course, at post-treatment, and again at 3-month follow-up. The satisfaction measures were administered at post-treatment. Controls completed the PHQ-9 and GAD-7 at the pre-and post-treatment time points of the treatment groups, and then began treatment.</p></sec><sec id="s2e"><title>Intervention</title><p>The Wellbeing Course is a new five lesson transdiagnostic online intervention based on models of cognitive behavioural and interpersonal therapies. The original Wellbeing Program developed by the researchers <xref rid="pone.0062873-Dear1" ref-type="bibr">[8]</xref>, <xref rid="pone.0062873-Titov2" ref-type="bibr">[9]</xref> was not available when the researchers moved institutions and, consequently, a new intervention was developed. This new course is based on a pragmatic model of psychotherapeutic change that assumes that symptoms of anxiety and depression are the result of unhelpful habits of thought and actions, that is, maladaptive cognitions and behaviours. Such unhelpful habits often develop over months or years and may become an entrenched part of a person&#x02019;s life. This model also assumes that interventions that are structured, systematic, and which require adherence and commitment over several months are more likely to facilitate sustained improvements than sporadic or unstructured therapy sessions, which may only result in short-term symptom relief.</p><p>Thus, the Wellbeing Course is a structured intervention that participants complete over an 8 week period. Participants are strongly encouraged to learn about and practice the psychological skills taught in the course, and to adopt these into their everyday lives. The course systematically teaches core psychological skills that aim to increase the frequency of cognitions and behaviours that promote emotional health, and reduce those that maintain distressing symptoms. Examples of the former include realistic thinking skills, planning, and problem solving skills, assertive communication, behavioural activation, and graded exposure. Examples of the latter include patterns of catastrophic and self-defeating thinking, passive or aggressive communication styles, avoidance, and behavioural inhibition. By doing so, this Course targets symptoms common to anxiety disorders and depression. The Wellbeing Course was designed as a low intensity intervention, which could be used as a standalone intervention, an intervention for those on waiting lists for traditional therapy, as an adjunct to traditional therapy, or to facilitate treatment gains post-treatment.</p><p>The Course comprises material both in didactic form, that is, text based instructions and information, and case-enhanced learning examples. Case-enhanced learning is informed by principles of Social Cognitive Theory (SCT) <xref rid="pone.0062873-Bandura1" ref-type="bibr">[33]</xref> and uses educational stories that identify a problem and a solution which an example (i.e., a case) resolves for the learner. The use of cases to facilitate learning is thought to assist in learning, adherence and engagement <xref rid="pone.0062873-Hinyard1" ref-type="bibr">[34]</xref> while reducing defensiveness <xref rid="pone.0062873-Hinyard1" ref-type="bibr">[34]</xref>, <xref rid="pone.0062873-Chang1" ref-type="bibr">[35]</xref>, <xref rid="pone.0062873-Wilson1" ref-type="bibr">[36]</xref>.</p><p>Lesson 1 of the Wellbeing Course includes information about the prevalence of anxiety disorders and depression, their role in affecting achievement of life goals, and how cognitive, behavioural, and physical symptoms maintain poor emotional health. Lesson 2 describes strategies for developing realistic cognitions. Lesson 3 describes physical de-arousal strategies and strategies for re-engaging in reinforcing activities. Lesson 4 describes avoidance and safety behaviours and principles of graded exposure. Lesson 5 describes principles of relapse prevention.</p><p>Each lesson is presented in a slide format combining text and photos, with approximately 60 slides per lesson, and 50 words per slide. Automated analyses of readability indicate the text has a mean Flesch-Kincaid Grade level of 6.1, a Simple Measure of Gobbledygook (SMOG) Index of 7, and Automated Readability Index of 5.3, indicating suitability for 8&#x02013;9 year olds. Participants are instructed to read lessons in order over 8 weeks. Lessons 1, 2, 3, 4, and 5 are available at the beginning of weeks 1, 2, 4, 5, and 7, respectively. This timetable provides participants with additional time for the most complex components of the intervention, namely skills for managing cognitive and behavioural symptoms. Recommended homework assignments are described in a <italic>Do It Yourself Guide</italic> for each lesson. Additional resources include materials about assertiveness, communication and problem solving skills, and sleep hygiene skills.</p></sec><sec id="s2f"><title>Procedure</title><p>TG and TEG participants received an email at the start of the Course providing guidelines and a recommended timetable to get the most out of the Course. TEG participants also received at least two additional emails per week during the Course. Some emails were triggered based on participant behaviour: specifically, emails were triggered when (1) participants completed each Lesson during the Course, and (2) if participants had not completed a Lesson within 7 days of it becoming available. Emails were also triggered according to the Course timeline: specifically, emails were triggered (1) at the beginning of each week when new Lessons became available or, if no new Lessons became available, to suggest some tasks for the week, and (2) at set times when participants were known to experience increases in symptoms or to have increased difficulties practicing skills (e.g., during the weeks where graded exposure is introduced). The emails were written and designed to (1) make sure participants always new about new content available on the site, (2) remind participants about unread materials, (3) reinforce progress and skills practice, (4) &#x02018;normalise&#x02019; the challenges of learning new skills, and (5) emphasise and explain that symptom reduction required gentle, but consistent, practice of the skills over time. Each email was brief and was comprised of 2 to 3 paragraphs containing 3 or 4 concise sentences. Each email used the participant&#x02019;s first name and was written to convey a warm and supportive tone. All participants consented to receive the emails and no emails contained personal or detailed clinical information.</p><p>Controls completed pre-treatment questionnaires at the same time as the treatment groups, but had no further contact with the researchers until post-treatment. Control group participants then received the same post-treatment questionnaires as the treatment groups and began treatment as soon as these questionnaires were complete. The control group participants received the same treatment as the TEG.</p></sec><sec id="s2g"><title>Statistical Methods</title><p>Participants who did not complete pre-treatment questionnaires were not included in any analyses. This was necessary as participants began the intervention in cohorts following randomisation. Group differences in demographic data and pre-treatment measures were analysed with one-way analysis of variance (ANOVAs) followed by <italic>t</italic>-tests with Bonferroni corrected <italic>p</italic> values and chi-square tests.</p><p>Two sets of analyses were conducted to examine the primary hypotheses. The mixed-models approach with an autoregressive covariance structured and using maximum likelihood estimation was identified as the best way to handle missing data at post-treatment and three month follow-up. The first set of analyses were conducted using the entire data set (i.e., the O<italic>verall Sample</italic>) and the second set of analyses were restricted to participants with elevated symptoms of both anxiety and depression (i.e., the <italic>Comorbid Sample</italic>), defined by pre-treatment scores above clinical cut-offs on both primary outcome measures (i.e., GAD-7&#x02265;8 and total PHQ-9&#x02265;10). Differences in questionnaire scores within and between groups at the different time points were examined using pairwise comparisons. Effect sizes (Cohen&#x02019;s <italic>d</italic>) and 95% effect size confidence intervals were calculated both within-group and between-group effects based on the pooled standard deviation. All analyses were performed in SPSS version 19.0 (SPSS, Inc., Chicago, IL).</p><p>As described in recent dissemination studies <xref rid="pone.0062873-Richards1" ref-type="bibr">[31]</xref>, pre-treatment, post-treatment and follow-up PHQ-9 and GAD-7 scores were compared with clinical cut-offs to provide an index of clinically significant <italic>remission</italic>. This was defined as the proportion of participants who initially scored at or above the clinical cut-offs and then subsequently below the clinical cut-offs. Finally, the number of times safety protocols were triggered because of elevated PHQ-9 scores and the proportion of participants with significant deterioration in PHQ-9 or GAD-7 scores were reported. The latter was calculated for each group based on a completer analysis and defined as an increase in PHQ-9 or GAD-7 scores of 5 or more points from pre-treatment.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Baseline Data</title><p>The mean age of participants was 41.30 years (SD&#x0200a;=&#x0200a;9.76), and 186 (74.4%) were women. Additional demographic details are included in <xref ref-type="table" rid="pone-0062873-t001">Table 1</xref>. A one way ANOVA and post-hoc tests revealed that Controls were older than TEG participants (<italic>F<sub>2, 254</sub></italic>&#x0200a;=&#x0200a;3.42, <italic>P</italic>&#x0200a;=&#x0200a;.034), and TG participants were less likely to be taking medication for mental health conditions than other participants (<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;6.20, <italic>P</italic>&#x0200a;=&#x0200a;.013). No other differences were found in demographic characteristics or in pre-treatment scores on the outcome measures (all <italic>P</italic>s&#x0003e;.05).</p><table-wrap id="pone-0062873-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0062873.t001</object-id><label>Table 1</label><caption><title>Group demographic characteristics for the Overall Sample.</title></caption><alternatives><graphic id="pone-0062873-t001-1" xlink:href="pone.0062873.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">
<italic>TEG (n&#x0200a;=&#x0200a;100)</italic>
</td><td colspan="2" align="left" rowspan="1">
<italic>TG (n&#x0200a;=&#x0200a;106)</italic>
</td><td colspan="2" align="left" rowspan="1">
<italic>Controls (n&#x0200a;=&#x0200a;51)</italic>
</td><td colspan="2" align="left" rowspan="1">
<italic>Total</italic>
</td><td align="left" rowspan="1" colspan="1">Statistical Significance</td></tr><tr><td align="left" rowspan="1" colspan="1">Variable</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">
<italic>N</italic>
</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">26.4</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">33.3</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">26.5</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;1.85, <italic>P</italic>&#x0200a;=&#x0200a;0.396</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">73.6</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">66.7</td><td align="left" rowspan="1" colspan="1">189</td><td align="left" rowspan="1" colspan="1">73.5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">40.31 (10.13)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">40.71 (9.07)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">44.45 (9.97)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">41.30 (9.76)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">
<italic>F</italic>
<sub>2,254</sub>&#x0200a;=&#x0200a;3.42, <italic>P</italic>&#x0200a;=&#x0200a;0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" rowspan="1" colspan="1">18&#x02013;59</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">20&#x02013;58</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">22&#x02013;59</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">18&#x02013;59</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Self-Identified Principal Problem</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Depression</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">33.0</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">27.4</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">45.1</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">33.1</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (6)&#x0200a;=&#x0200a;9.69, <italic>P</italic>&#x0200a;=&#x0200a;0.138</td></tr><tr><td align="left" rowspan="1" colspan="1">Generalised Anxiety Disorder</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">28.0</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">41.5</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">23.5</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">32.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Panic Disorder</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">17.0</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">10.4</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">11.8</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">13.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Social Phobia</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">22.0</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">20.8</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">19.6</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">21.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Marital Status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Single/Never Married</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">31.0</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">23.6</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">23.5</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">26.5</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (4)&#x0200a;=&#x0200a;7.18, <italic>P</italic>&#x0200a;=&#x0200a;0.127</td></tr><tr><td align="left" rowspan="1" colspan="1">Married/De Facto</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">57.0</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">66.0</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">52.9</td><td align="left" rowspan="1" colspan="1">154</td><td align="left" rowspan="1" colspan="1">59.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Separated/Divorced/Widowed</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">12.0</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">10.4</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">23.5</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">13.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Education</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.4</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (6)&#x0200a;=&#x0200a;3.99, <italic>P</italic>&#x0200a;=&#x0200a;0.677</td></tr><tr><td align="left" rowspan="1" colspan="1">High school</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">19.0</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">17.0</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">17.6</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">17.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Trade/Technical Certificate</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">21.0</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">14.2</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">15.7</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">17.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diploma/Degree</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">59.0</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">68.9</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">66.7</td><td align="left" rowspan="1" colspan="1">166</td><td align="left" rowspan="1" colspan="1">64.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Employment Status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Full time</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">49.0</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">46.2</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">35.3</td><td align="left" rowspan="1" colspan="1">116</td><td align="left" rowspan="1" colspan="1">45.1</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (4)&#x0200a;=&#x0200a;5.26, <italic>p</italic>&#x0200a;=&#x0200a;.325</td></tr><tr><td align="left" rowspan="1" colspan="1">Part time/Student</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">31.0</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">32.1</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">35.3</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">32.3</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Unemployed, Retired or Disabled</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">21.7</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">29.4</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">22.6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Previous Mental Health Treatment</bold>
</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">84.0</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">82.1</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">80.4</td><td align="left" rowspan="1" colspan="1">212</td><td align="left" rowspan="1" colspan="1">82.5</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;0.326, <italic>P</italic>&#x0200a;=&#x0200a;0.850</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Taking Medication for Mental Health Condition</bold>
</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">45.0</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">47.1</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">38.5</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;8.02, <italic>P</italic>&#x0200a;=&#x0200a;0.018</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>
<italic>Note.</italic> TEG: Treatment Plus Automated Email Group. TG: Treatment Group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Adherence and Attrition</title><p>The flow is shown in <xref ref-type="fig" rid="pone-0062873-g001">Figure 1</xref>. More TEG participants (58.0%) completed the course, defined as reading the five lessons within the eight weeks, than TG (35.8%) participants (<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;10.15, <italic>P</italic>&#x0200a;=&#x0200a;.001) in the Overall Sample. A similar pattern was observed in the Comorbid Sample with more TEG participants (56.7%) completing the course than TG (29.6%) participants (<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;8.44, <italic>P</italic>&#x0200a;=&#x0200a;.004). As indicated in <xref ref-type="fig" rid="pone-0062873-g001">Figure 1</xref>, considerably more TG participants (34.0%) terminated before completing lesson 3 than TEG participants (11.0%). Completers did not differ from non-completers on either PHQ-9 or GAD-7 pre-treatment scores (<italic>F<sub>1, 204</sub></italic>&#x0200a;=&#x0200a;0.39&#x02013;1.67, <italic>P</italic>&#x0003e;.05).</p><fig id="pone-0062873-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0062873.g001</object-id><label>Figure 1</label><caption><title>Wellbeing study flow chart.</title><p>PHQ-9, Patient Health Questionnaire &#x02013;9 Item. TEG: Treatment Plus Automated Email Group. TG: Treatment Group.</p></caption><graphic xlink:href="pone.0062873.g001"/></fig><p>Post-treatment data were collected from 84.0% TEG, 86.8% TG, and 84.3% Control participants. Three-month follow-up data were collected from 79.0% TEG and 79.2% TG participants. ANOVAs revealed that those who did not complete follow-up questionnaires had significantly higher pre-treatment PHQ-9 scores (<italic>F<sub>1, 204</sub></italic>&#x0200a;=&#x0200a;9.33, <italic>P</italic>&#x0200a;=&#x0200a;.003) but not GAD-7 scores (<italic>F<sub>1, 204</sub></italic>&#x0200a;=&#x0200a;0.06, <italic>P</italic>&#x0200a;=&#x0200a;.80), than questionnaire completers.</p></sec><sec id="s3c"><title>Primary Outcome Measures</title><p>Means for the PHQ-9 and GAD-7 for the Overall and Comorbid Samples are included in <xref ref-type="table" rid="pone-0062873-t002">Table 2</xref>. The means for the Control Group after they received the same treatment as the TEG are also shown in <xref ref-type="table" rid="pone-0062873-t002">Table 2</xref>. Changes in PHQ-9 and GAD-7 scores for the Overall and Comorbid Samples are shown in <xref ref-type="fig" rid="pone-0062873-g002">Figure 2</xref>.</p><fig id="pone-0062873-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0062873.g002</object-id><label>Figure 2</label><caption><title>Means for the PHQ-9 and GAD-7 for the Overall and Comorbid Samples.</title><p>Note: TEG: Treatment plus automated email group. TG: Treatment group. PHQ-9: Patient Health Questionnaire-9 Item. GAD-7: Generalised Anxiety Disorder-7 Item.</p></caption><graphic xlink:href="pone.0062873.g002"/></fig><table-wrap id="pone-0062873-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0062873.t002</object-id><label>Table 2</label><caption><title>Results of outcome measures for the Overall Sample: Observed and Estimated Means, standard deviations, confidence intervals and effect sizes (Cohen&#x02019;s <italic>d</italic>) for each group.</title></caption><alternatives><graphic id="pone-0062873-t002-2" xlink:href="pone.0062873.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N</td><td colspan="3" align="left" rowspan="1">Observed Means</td><td colspan="3" align="left" rowspan="1">Estimated Means</td><td colspan="5" align="left" rowspan="1">Effect sizes (based on estimated means)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">Post</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">Post</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Within GroupPre-post</td><td align="left" rowspan="1" colspan="1">Post Between Group TEGvs. TG</td><td align="left" rowspan="1" colspan="1">Post Between Group vs. Control</td><td align="left" rowspan="1" colspan="1">Within Group Pre-follow</td><td align="left" rowspan="1" colspan="1">Follow-up Between Group TEG vs. TG</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>PHQ-9</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TEG</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">11.71 (4.72)</td><td align="left" rowspan="1" colspan="1">6.73 (4.50)</td><td align="left" rowspan="1" colspan="1">6.24 (4.42)</td><td align="left" rowspan="1" colspan="1">11.71 (4.95)</td><td align="left" rowspan="1" colspan="1">6.79 (5.31)</td><td align="left" rowspan="1" colspan="1">6.49 (5.35)</td><td align="left" rowspan="1" colspan="1">.96 (.66&#x02013;1.25)</td><td align="left" rowspan="1" colspan="1">.14 (&#x02212;.14&#x02013;.41)</td><td align="left" rowspan="1" colspan="1">.68 (.33&#x02013;1.03)</td><td align="left" rowspan="1" colspan="1">1.01 (.71&#x02013;1.30)</td><td align="left" rowspan="1" colspan="1">.07 (&#x02212;.20&#x02013;.34)</td></tr><tr><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">106</td><td align="left" rowspan="1" colspan="1">10.99 (4.92)</td><td align="left" rowspan="1" colspan="1">7.41 (5.91)</td><td align="left" rowspan="1" colspan="1">6.38 (5.07)</td><td align="left" rowspan="1" colspan="1">10.99 (4.95)</td><td align="left" rowspan="1" colspan="1">7.51 (5.28)</td><td align="left" rowspan="1" colspan="1">6.87 (5.34)</td><td align="left" rowspan="1" colspan="1">.68 (.40&#x02013;.95)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">.55 (.21&#x02013;89)</td><td align="left" rowspan="1" colspan="1">.80 (.52&#x02013;1.08)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">10.53 (4.63)</td><td align="left" rowspan="1" colspan="1">10.50 (5.04)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">10.52 (4.94)</td><td align="left" rowspan="1" colspan="1">10.44 (5.41)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">.02 (&#x02212;.37 &#x02013;.40)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>GAD-7</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TEG</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">10.98 (4.23)</td><td align="left" rowspan="1" colspan="1">5.75 (3.78)</td><td align="left" rowspan="1" colspan="1">5.51 (4.13)</td><td align="left" rowspan="1" colspan="1">10.98 (4.57)</td><td align="left" rowspan="1" colspan="1">5.85 (4.89)</td><td align="left" rowspan="1" colspan="1">5.42 (4.90)</td><td align="left" rowspan="1" colspan="1">1.08 (.78&#x02013;1.38)</td><td align="left" rowspan="1" colspan="1">.20 (&#x02212;.07&#x02013;.47)</td><td align="left" rowspan="1" colspan="1">.58 (.23&#x02212;.92)</td><td align="left" rowspan="1" colspan="1">1.17 (.87&#x02013;1.47)</td><td align="left" rowspan="1" colspan="1">.09 (&#x02212;.18&#x02013;.36)</td></tr><tr><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">106</td><td align="left" rowspan="1" colspan="1">10.40 (4.98)</td><td align="left" rowspan="1" colspan="1">6.80 (5.62)</td><td align="left" rowspan="1" colspan="1">5.60 (4.25)</td><td align="left" rowspan="1" colspan="1">10.39 (4.57)</td><td align="left" rowspan="1" colspan="1">6.83 (4.83)</td><td align="left" rowspan="1" colspan="1">5.87 (4.89)</td><td align="left" rowspan="1" colspan="1">.76 (.48&#x02013;1.03)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">.38 (.04&#x02013;.72)</td><td align="left" rowspan="1" colspan="1">.96 (.67&#x02013;1.24)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">9.37 (4.39)</td><td align="left" rowspan="1" colspan="1">8.75 (4.44)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">9.37 (4.56)</td><td align="left" rowspan="1" colspan="1">8.69 (4.98)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">.14 (&#x02212;.25&#x02013;.53)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Control (In</bold>
<bold>Treatment)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GAD-7</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">8.76 (4.44)</td><td align="left" rowspan="1" colspan="1">5.58 (4.17)</td><td align="left" rowspan="1" colspan="1">4.53 (3.43)</td><td align="left" rowspan="1" colspan="1">8.76 (4.23)</td><td align="left" rowspan="1" colspan="1">5.63 (4.54)</td><td align="left" rowspan="1" colspan="1">4.74 (4.52)</td><td align="left" rowspan="1" colspan="1">.71 (.27&#x02013;1.15)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">.92 (.46 (1.36)</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">PHQ-9</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">10.50 (5.04)</td><td align="left" rowspan="1" colspan="1">5.69 (4.08)</td><td align="left" rowspan="1" colspan="1">5.67 (4.66)</td><td align="left" rowspan="1" colspan="1">10.50 (4.85)</td><td align="left" rowspan="1" colspan="1">6.05 (5.15)</td><td align="left" rowspan="1" colspan="1">6.11 (5.08)</td><td align="left" rowspan="1" colspan="1">.89 (.43&#x02013;1.33)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">.88 (.43&#x02013;1.32)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>
<italic>Note.</italic> Standard deviations and confidence intervals are shown in parentheses. TEG: Treatment Plus Automated Email Group. TG: Treatment Group; Pre: Pre-treatment, Post: Post-treatment; Follow-up: 3 month follow-up; PHQ-9: Patient Health Questionnaire 9-Item; GAD-7: Generalised Anxiety Disorder 7-Item.</p></fn></table-wrap-foot></table-wrap><sec id="s3c1"><title>Overall Sample</title><p>The mixed-models analyses examining PHQ-9 scores (<xref ref-type="table" rid="pone-0062873-t002">Table 2</xref>) revealed a significant effect for Time (<italic>F<sub>2, 373</sub></italic>&#x0200a;=&#x0200a;61.66, <italic>P</italic>&#x0003c;.001) and a significant Time by Group interaction, (<italic>F<sub>3, 416</sub></italic>&#x0200a;=&#x0200a;6.79, <italic>P</italic>&#x0003c;.001), but no significant effect for Group (<italic>F<sub>2, 277</sub></italic>&#x0200a;=&#x0200a;1.882, <italic>P</italic>&#x0200a;=&#x0200a;.154). Pairwise comparisons revealed significant differences between TEG and Controls (<italic>P</italic>&#x0003c;.001) and between TG and Controls (<italic>P</italic>&#x0200a;=&#x0200a;.001) at post-treatment, but no significant difference between treatment groups at post-treatment (<italic>P</italic>&#x0200a;=&#x0200a;.333) or three month follow-up (P&#x0200a;=&#x0200a;.611).</p><p>Similarly, the analyses examining GAD-7 scores revealed a significant effect for Time (<italic>F<sub>2, 370</sub></italic>&#x0200a;=&#x0200a;105.07, <italic>P</italic>&#x0003c;.001) and a significant Time by Group interaction, (<italic>F<sub>3, 416</sub></italic>&#x0200a;=&#x0200a;7.43, <italic>P</italic>&#x0003c;.001), but no significant effect for Group (<italic>F<sub>2, 269</sub></italic>&#x0200a;=&#x0200a;0.487, <italic>P</italic>&#x0200a;=&#x0200a;.615). Pairwise comparisons revealed significant differences between TEG and Controls (<italic>P</italic>&#x0200a;=&#x0200a;.001) and between TG and Controls (<italic>P</italic>&#x0200a;=&#x0200a;.0028) at post-treatment, but no significant difference between treatment groups at post-treatment (<italic>P</italic>&#x0200a;=&#x0200a;.151) or three month follow-up (<italic>P</italic>&#x0200a;=&#x0200a;.505).</p></sec><sec id="s3c2"><title>Comorbid Sample</title><p>The mixed-models analyses examining PHQ-9 scores (<xref ref-type="table" rid="pone-0062873-t002">Table 2</xref>) for the Comorbid Sample revealed a significant effect for Time (<italic>F<sub>2, 158</sub></italic>&#x0200a;=&#x0200a;76.81, <italic>P</italic>&#x0003c;.001) and Group (<italic>F<sub>1, 107</sub></italic>&#x0200a;=&#x0200a;5.03, <italic>P</italic>&#x0200a;=&#x0200a;.027), and a significant Time by Group interaction, (<italic>F<sub>2, 158</sub></italic>&#x0200a;=&#x0200a;4.03, <italic>P</italic>&#x0200a;=&#x0200a;.020. Pairwise comparisons revealed that both groups improved significantly from pre-treatment to post-treatment (<italic>P</italic>s&#x0003c;.001), but not from post-treatment to follow-up (<italic>P</italic>&#x0003e;.099). However, the pairwise comparisons also revealed significant differences between TEG and TG Groups at post-treatment (<italic>P</italic>&#x0200a;=&#x0200a;.008) and three month follow-up (<italic>P</italic>&#x0200a;=&#x0200a;.015) with the TEG Group reporting lower symptoms on the PHQ-9 at both time points.</p><p>The analyses examining GAD-7 scores revealed a significant Time by Group interaction, (<italic>F<sub>2, 150</sub></italic>&#x0200a;=&#x0200a;3.78, <italic>P</italic>&#x0200a;=&#x0200a;.025) and significant main effects for Time (<italic>F<sub>2, 150</sub></italic>&#x0200a;=&#x0200a;106.34, <italic>P</italic>&#x0003c;.001) and Group (<italic>F<sub>1, 99</sub></italic>&#x0200a;=&#x0200a;5.51, <italic>P</italic>&#x0200a;=&#x0200a;.021). Pairwise comparisons revealed that both groups improved significantly from pre-treatment to post-treatment (<italic>P</italic>s&#x0003c;.001), but that the TG Group improved significantly from post-treatment to follow-up (<italic>P</italic>&#x0200a;=&#x0200a;.033) where the TEG Group showed no significant change in GAD-7 scores from post-treatment to follow-up (<italic>P</italic>&#x0200a;=&#x0200a;.320). The pairwise comparisons also revealed the TEG Group reported significantly lower symptoms than the TG Group at post-treatment (<italic>P</italic>&#x0200a;=&#x0200a;.002) and three month follow-up (<italic>P</italic>&#x0200a;=&#x0200a;.031).</p></sec></sec><sec id="s3d"><title>Effect Sizes</title><p>Within- and between-group effect sizes for the outcome measures are included in <xref ref-type="table" rid="pone-0062873-t002">Tables 2</xref> and <xref ref-type="table" rid="pone-0062873-t003">3</xref>. For both the Overall and Comorbid Samples large (&#x02265;0.8) within-group effect sizes were found for the TEG, and moderate (0.5&#x0003c;0.8) to large within-group effect sizes were found for the TG. Small (&#x0003c;0.5) between-group effect sizes were found between the two treatment groups, while moderate between-group effect sizes were found for the diagnostic samples.</p><table-wrap id="pone-0062873-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0062873.t003</object-id><label>Table 3</label><caption><title>Results of outcome measures for the Comorbid Sample (cut-offs on both PHQ-9 and GAD-7): Observed and Estimated Means, standard deviations, confidence intervals and effect sizes (Cohen&#x02019;s <italic>d</italic>) for each group.</title></caption><alternatives><graphic id="pone-0062873-t003-3" xlink:href="pone.0062873.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n</td><td colspan="3" align="left" rowspan="1">Observed Means</td><td colspan="3" align="left" rowspan="1">Estimated Means</td><td colspan="4" align="left" rowspan="1">Effect sizes (based on estimated means)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">Post</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">Post</td><td align="left" rowspan="1" colspan="1">Follow-up</td><td align="left" rowspan="1" colspan="1">Within Group Pre-post</td><td align="left" rowspan="1" colspan="1">Post Between Group TEG vs. TG</td><td align="left" rowspan="1" colspan="1">Within Group Pre-follow</td><td align="left" rowspan="1" colspan="1">Follow-up Between Group TEG vs. TG</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>PHQ-9</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TEG</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">14.64 (3.34)</td><td align="left" rowspan="1" colspan="1">7.58 (4.60)</td><td align="left" rowspan="1" colspan="1">6.34 (4.58)</td><td align="left" rowspan="1" colspan="1">14.63 (4.61)</td><td align="left" rowspan="1" colspan="1">7.69 (4.95)</td><td align="left" rowspan="1" colspan="1">6.47 (4.99)</td><td align="left" rowspan="1" colspan="1">1.45 (.99&#x02013;1.89)</td><td align="left" rowspan="1" colspan="1">.56 (.14&#x02013;.96)</td><td align="left" rowspan="1" colspan="1">1.70 (1.21&#x02013;2.16)</td><td align="left" rowspan="1" colspan="1">.51 (.09&#x02013;.92)</td></tr><tr><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">14.39 (3.33)</td><td align="left" rowspan="1" colspan="1">10.57 (6.16)</td><td align="left" rowspan="1" colspan="1">8.94 (6.27)</td><td align="left" rowspan="1" colspan="1">14.39 (4.61)</td><td align="left" rowspan="1" colspan="1">10.48 (5.10)</td><td align="left" rowspan="1" colspan="1">9.09 (5.28)</td><td align="left" rowspan="1" colspan="1">.80 (.37&#x02013;1.22)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.07 (.62&#x02013;1.50)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>GAD-7</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TEG</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">14.30 (3.01)</td><td align="left" rowspan="1" colspan="1">6.70 (4.39)</td><td align="left" rowspan="1" colspan="1">6.39 (4.30)</td><td align="left" rowspan="1" colspan="1">14.29 (4.21)</td><td align="left" rowspan="1" colspan="1">7.02 (4.71)</td><td align="left" rowspan="1" colspan="1">6.34 (4.58)</td><td align="left" rowspan="1" colspan="1">2.02 (1.51&#x02013;2.50)</td><td align="left" rowspan="1" colspan="1">.65 (.22&#x02013;1.06)</td><td align="left" rowspan="1" colspan="1">2.05 (1.54&#x02013;2.54)</td><td align="left" rowspan="1" colspan="1">.45 (.04&#x02013;.86)</td></tr><tr><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">14.33 (3.36)</td><td align="left" rowspan="1" colspan="1">10.16 (6.07)</td><td align="left" rowspan="1" colspan="1">8.50 (4.62)</td><td align="left" rowspan="1" colspan="1">14.32 (4.27)</td><td align="left" rowspan="1" colspan="1">10.01 (4.53)</td><td align="left" rowspan="1" colspan="1">8.46 (4.83)</td><td align="left" rowspan="1" colspan="1">.96 (.52&#x02013;1.38)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.29 (.83&#x02013;1.72)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>
<italic>Note.</italic> Standard deviations and confidence intervals are shown in parentheses. TEG: Treatment Plus Automated Email Group. TG: Treatment Group; Pre: Pre-treatment, Post: Post-treatment; Follow-up: 3-month follow-up; PHQ-9: Patient Health Questionnaire 9-Item; GAD-7: Generalised Anxiety Disorder 7-Item.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><title>Clinical Significance</title><sec id="s3e1"><title>Overall Sample</title><p>With respect to remission, significantly more TEG (55.9% and 57.9%) and more TG (53.7% and 56.8%) participants scored below the PHQ-9 and GAD-7 clinical cut-offs than Controls (24.1% and 21.9%) at post-treatment, respectively, with no difference between treatment groups (<xref ref-type="table" rid="pone-0062873-t004">Table 4</xref>). These gains were sustained at follow-up, again with no difference between treatment groups.</p><table-wrap id="pone-0062873-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0062873.t004</object-id><label>Table 4</label><caption><title>Proportion of participants in the Overall and Diagnostic Sample, by group, above and below cut-off scores of clinical significance (remission).</title></caption><alternatives><graphic id="pone-0062873-t004-4" xlink:href="pone.0062873.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Overall Sample</td><td colspan="2" align="left" rowspan="1">TEG</td><td colspan="2" align="left" rowspan="1">TG</td><td colspan="2" align="left" rowspan="1">Control</td><td colspan="2" align="left" rowspan="1">Chi Square</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">%</td><td align="left" rowspan="1" colspan="1">Between group</td><td align="left" rowspan="1" colspan="1">TGE vs. TG</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>PHQ-9</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pre-treatment score &#x02265;10/Total</td><td align="left" rowspan="1" colspan="1">68/100</td><td align="left" rowspan="1" colspan="1">68.0</td><td align="left" rowspan="1" colspan="1">67/106</td><td align="left" rowspan="1" colspan="1">63.2</td><td align="left" rowspan="1" colspan="1">29/51</td><td align="left" rowspan="1" colspan="1">56.9</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;1.84, <italic>P</italic>&#x0200a;=&#x0200a;0.398</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Post-treatment score &#x0003c;10 (Remission)</td><td align="left" rowspan="1" colspan="1">38/68</td><td align="left" rowspan="1" colspan="1">55.9</td><td align="left" rowspan="1" colspan="1">36/67</td><td align="left" rowspan="1" colspan="1">53.7</td><td align="left" rowspan="1" colspan="1">7/29</td><td align="left" rowspan="1" colspan="1">24.1</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;9.05, <italic>P</italic>&#x0200a;=&#x0200a;0.011</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;0.06, <italic>P</italic>&#x0200a;=&#x0200a;0.802</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up score &#x0003c;10 (Remission)</td><td align="left" rowspan="1" colspan="1">45/68</td><td align="left" rowspan="1" colspan="1">66.2</td><td align="left" rowspan="1" colspan="1">42/67</td><td align="left" rowspan="1" colspan="1">62.7</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;0.18, <italic>P</italic>&#x0200a;=&#x0200a;0.672</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>GAD-7</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pre-treatment score &#x02265;8/Total</td><td align="left" rowspan="1" colspan="1">76/100</td><td align="left" rowspan="1" colspan="1">76.0</td><td align="left" rowspan="1" colspan="1">74/106</td><td align="left" rowspan="1" colspan="1">69.8</td><td align="left" rowspan="1" colspan="1">32/51</td><td align="left" rowspan="1" colspan="1">62.7</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;2.96, <italic>P</italic>&#x0200a;=&#x0200a;0.228</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Post-treatment score &#x0003c;8 (Remission)</td><td align="left" rowspan="1" colspan="1">44/76</td><td align="left" rowspan="1" colspan="1">57.9</td><td align="left" rowspan="1" colspan="1">42/74</td><td align="left" rowspan="1" colspan="1">56.8</td><td align="left" rowspan="1" colspan="1">7/32</td><td align="left" rowspan="1" colspan="1">21.9</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;13.20, <italic>P</italic>&#x0200a;=&#x0200a;0.001</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;0.02, <italic>P</italic>&#x0200a;=&#x0200a;0.888</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up score &#x0003c;8 (Remission)</td><td align="left" rowspan="1" colspan="1">45/76</td><td align="left" rowspan="1" colspan="1">59.2</td><td align="left" rowspan="1" colspan="1">44/74</td><td align="left" rowspan="1" colspan="1">60.3</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;0.00, <italic>P</italic>&#x0200a;=&#x0200a;0.975</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Diagnostic Sample</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Pre-treatment PHQ-9 score &#x02265;10 and GAD-7 score &#x02265;8/Total</td><td align="left" rowspan="1" colspan="1">60/100</td><td align="left" rowspan="1" colspan="1">60.0</td><td align="left" rowspan="1" colspan="1">54/106</td><td align="left" rowspan="1" colspan="1">50.9</td><td align="left" rowspan="1" colspan="1">22/51</td><td align="left" rowspan="1" colspan="1">43.1</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;4.14, <italic>P</italic>&#x0200a;=&#x0200a;0.126</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Post-treatment PHQ-9 score &#x0003c;10 and GAD-7 score &#x0003c;8 (Remission)</td><td align="left" rowspan="1" colspan="1">28/60</td><td align="left" rowspan="1" colspan="1">46.7</td><td align="left" rowspan="1" colspan="1">21/54</td><td align="left" rowspan="1" colspan="1">38.9</td><td align="left" rowspan="1" colspan="1">4/22</td><td align="left" rowspan="1" colspan="1">18.2</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (2)&#x0200a;=&#x0200a;5.49, <italic>P</italic>&#x0200a;=&#x0200a;0.064</td><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;0.70, <italic>P</italic>&#x0200a;=&#x0200a;0.402</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up PHQ-9 score &#x0003c;10 and GAD-7 score &#x0003c;8 (Remission)</td><td align="left" rowspan="1" colspan="1">30/60</td><td align="left" rowspan="1" colspan="1">50.0</td><td align="left" rowspan="1" colspan="1">23/54</td><td align="left" rowspan="1" colspan="1">42.6</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold><italic>&#x003c7;</italic></bold>
<bold><sup>2</sup></bold> (1)&#x0200a;=&#x0200a;0.63, <italic>P</italic>&#x0200a;=&#x0200a;0.429</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>
<italic>Note.</italic> TEG: Treatment Plus Automated Email Group. TG: Treatment Group.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e2"><title>Comorbid Sample</title><p>At post-treatment, significantly more TEG (46.7%) and TG (38.9%) participants were below both cut-offs than Controls (18.2%), with no difference between treatment groups (<xref ref-type="table" rid="pone-0062873-t004">Table 4</xref>). These levels of remission were sustained at follow-up, again with no difference between treatment groups.</p></sec></sec><sec id="s3f"><title>Treatment Satisfaction</title><p>At post-treatment, 71/74 (95.9%) TEG and 76/80 (95%) TG participants reported it was &#x02018;<italic>worth their time doing the course&#x02019;</italic>, and 72/74 (97.3%) TGE and 74/79 (93.7%) TG participants reported they would &#x02018;<italic>recommend this course to a friend with anxiety or depression&#x02019;</italic>. Chi-squared analyses failed to reveal any differences in these satisfaction ratings (<italic>&#x003c7;</italic>
<sup>2</sup> (2&#x02013;3) range&#x0200a;=&#x0200a;0.76&#x02013;2.82, <italic>P</italic>&#x0003e;.05).</p></sec><sec id="s3g"><title>Safety</title><p>Participants&#x02019; responses to the PHQ-9 were automatically monitored and those whose PHQ-9 total scores increased from pre-treatment by more than 5 points and who also had a total score of &#x02265;15, indicating the presence of moderately severe depression were sent an automated email providing instructions about how to contact crisis services in the event of a mental health emergency. Those whose PHQ-9 scores were above 20, indicating severe depression, or scoring &#x02018;3&#x02019; to question 9 of the PHQ-9, were telephoned by the researchers who conducted an assessment and provided management. Five (5.0%) TEG, 1.9% TG, and no Controls received emails, and an additional 3.0% TEG, 2.8% TG, and 2.0% Control participants received both telephone calls and emails. The remainder of participants did not receive contact from the researchers until the 8 weeks had elapsed.</p></sec><sec id="s3h"><title>Deterioration</title><sec id="s3h1"><title>Overall Sample</title><p>At post-treatment and follow-up up to 4.0% of TEG, 7.5% of TG and 13.7% of Control participants obtained PHQ-9 or GAD-7 scores five or more points higher compared to pre-treatment.</p></sec><sec id="s3h2"><title>Comorbid Sample</title><p>At post-treatment and follow-up, up to 2.0% of TEG, 7.5% of TG and 5.9% of Control participants obtained PHQ-9 or GAD-7 scores five or more points higher compared to pre-treatment.</p></sec></sec><sec id="s3i"><title>Control Group Participants</title><p>Forty one of the 51 Control group participants elected to begin the Wellbeing Course after the Treatment Groups completed, and received the same treatment as the TEG. Twenty two of 41 (53.7%) Control Group participants completed the course within the 8 weeks, and post-treatment data and 3-month follow-up were collected from 87.8% and 87.8% participants, respectively.</p><p>The mixed-models analyses on the Control Group during treatment revealed significant main effects for Time on both the PHQ-9 (<italic>F<sub>2, 69</sub></italic>&#x0200a;=&#x0200a;21.11, <italic>P</italic>&#x0003c;.001) and GAD-7 (<italic>F<sub>2, 68</sub></italic>&#x0200a;=&#x0200a;14.55, <italic>P</italic>&#x0003c;.001). Pairwise comparisons revealed significant improvements on both the PHQ-9 and GAD-7 from pre-treatment to post-treatment (<italic>P</italic>&#x0003c;.001), but not post-treatment to 3-month follow-up (<italic>P</italic>&#x0003e;.257). These changes corresponded to effect sizes from pre-treatment to follow-up of 0.88 and 0.92 on the PHQ-9 and GAD-7, respectively.</p><p>With respect to remission, at post-treatment, 69.6% and 61.5% of Control Group participants scored below the PHQ-9 and GAD-7 clinical cut-offs, respectively, and these gains were sustained at follow-up. Ninety seven percent of Control group participants reported it was worth their time doing the Course, and 94% reported they would refer a friend.</p></sec></sec><sec id="s4"><title>Discussion</title><p>The Wellbeing Course resulted in clinically significant reductions in symptoms of anxiety and depression related to a waitlist control group. These results indicated automated emails increased completion rates in a self-guided iPT intervention for people with anxiety and depression from 36% to 58%. No overall differences were found between participants who did and did not receive automated emails during the intervention in symptoms of anxiety or depression at post-treatment or follow-up. However, significant differences were found between participants who did or did not receive emails for elevated symptoms of both anxiety and depression. Specifically, those participants with elevated symptoms who received automated emails reported significantly less symptoms of anxiety and depression at post-treatment and follow-up compared with those who did not. These differences corresponded to moderate between-group effect sizes at post-treatment (<italic>d</italic>&#x0200a;=&#x0200a;0.56 and 0.65) and follow-up (<italic>d</italic>&#x0200a;=&#x0200a;0.45 and 0.51). Importantly, treatment satisfaction was high and the results were replicated in the Control Group, providing preliminary evidence for the reliability of automated emails in facilitating outcomes.</p><p>The present results are consistent with previous studies reporting the effectiveness of automated self-guided internet treatments for depression or anxiety, but are of a greater magnitude <xref rid="pone.0062873-Christensen1" ref-type="bibr">[12]</xref>, <xref rid="pone.0062873-Farvolden1" ref-type="bibr">[13]</xref>, <xref rid="pone.0062873-Clarke1" ref-type="bibr">[15]</xref>, <xref rid="pone.0062873-Meyer1" ref-type="bibr">[37]</xref>. These results also compare favourably with those obtained from trials of transdiagnostic iPT involving clinician guidance <xref rid="pone.0062873-Johnston1" ref-type="bibr">[7]</xref>, <xref rid="pone.0062873-Dear1" ref-type="bibr">[8]</xref>, <xref rid="pone.0062873-Titov2" ref-type="bibr">[9]</xref>, trials of clinician-guided transdiagnostic interventions administered face-to-face <xref rid="pone.0062873-McEvoy1" ref-type="bibr">[38]</xref>, and with results from implementation trials in the UK IAPT service <xref rid="pone.0062873-Richards1" ref-type="bibr">[31]</xref>. However, caution should be exercised in making comparisons across studies due to differences in samples, inclusion criteria, and methodologies.</p><p>The overall results indicate that adding automated emails can facilitate adherence and outcomes in self-guided internet-delivered interventions. These benefits are stronger for those with comorbid and more severe symptoms. Unfortunately, no firm conclusions can be drawn concerning how emails facilitated adherence or clinical outcomes in the present trial. However, the results parallel an extensive literature that indicates the benefits of minimal therapist contact added to self-help programs <xref rid="pone.0062873-Meyer2" ref-type="bibr">[39]</xref>, <xref rid="pone.0062873-Cuijpers2" ref-type="bibr">[40]</xref>. Within this context therapists are likely to enhance motivation to continue in the course and engage in therapeutic activities. It is possible that automated emails serve the same motivational purpose and act in a similar fashion to a therapist, albeit in a less costly manner. If this is true, it would suggest that maximising the motivational efficacy or tailoring of automated emails might produce even stronger effects.</p><sec id="s4a"><title>Implications</title><p>These results indicate that, contrary to earlier reports <xref rid="pone.0062873-Gellatly1" ref-type="bibr">[41]</xref>, outcomes of self-guided internet-delivered interventions are beginning to approximate those obtained when support is provided by a therapist, at least, for populations attracted to online clinical trials. These results provide support for a model of psychotherapeutic change that emphasises the importance of systematically learning, practicing, and adopting core psychological skills that help to change unhelpful habits of thought and action. Systematically examining other strategies to promote engagement and adherence in self-guided iPT interventions is likely to further improve outcomes in iPT and will also have utility across a broad range of health conditions. We suspect the use of case-enhanced learning strategies in the course content facilitated engagement and adherence and, as noted by others, providing a clear deadline and expectations of feedback may also facilitate adherence and clinical outcomes <xref rid="pone.0062873-McEvoy1" ref-type="bibr">[38]</xref>.</p><p>Clinically effective self-guided iPT interventions are likely to be integrated with traditional models of care as therapists are more likely to refer consumers to self-guided interventions that are acceptable, engaging and effective. The results of the present study extend recent studies indicating that, following a therapist-administered structured diagnostic interview, consumers can obtain considerable benefit from a self-guided iPT intervention <xref rid="pone.0062873-Titov3" ref-type="bibr">[17]</xref>, <xref rid="pone.0062873-Christensen2" ref-type="bibr">[42]</xref>, <xref rid="pone.0062873-Berger1" ref-type="bibr">[43]</xref>, <xref rid="pone.0062873-Furmark1" ref-type="bibr">[44]</xref>. Those who do not benefit from the self-guided intervention or who wish for more support can be subsequently referred for a more intense intervention. This simple stepped model has considerable potential for improving the capacity of existing mental health services, although needs to be tested.</p><p>Notwithstanding these encouraging findings, these results indicate that risk of deterioration is not insignificant. Between 5 and 8% of treatment group participants required intervention and, although this proportion will vary depending on the criteria used, they indicate that some people accessing publicly available websites will have significant psychological distress. Consequently, attention must be given to protocols for facilitating safety and referral to crisis services.</p></sec><sec id="s4b"><title>Limitations</title><p>The generalisability of these findings needs to be considered in the context of the research design and participants. We aimed to simulate an intervention available on an open-access website. Thus, although participants applied independently and did not have contact with researchers until post-treatment, they were required to apply for the trial raising the potential of self-selected bias. However, a recent comparison of demographic and symptom profiles of participants in internet trials with those identified in epidemiological samples indicates the results of such trials may generalise to the wider population <xref rid="pone.0062873-Titov7" ref-type="bibr">[45]</xref>, although those results should be replicated with other samples. Unfortunately, no firm conclusions can be drawn concerning mechanisms through which emails facilitated outcomes and it is also notable that, in the overall sample, significant improvements in clinical outcomes were observed despite many participants not completing the whole Course. This is likely explained by the fact that, despite not completing the Course, most participants were exposed to significant levels of clinical content. Future research would, however, benefit from focusing on what level of clinical content is required to be reviewed or used in order to maximize and sustain clinical outcomes over the longer term.</p><p>While significant improvements were observed on symptoms of anxiety and depression, we did not conduct analyses on symptom measures relevant to specific anxiety disorders. In order to simulate an automated and publically available website the present study also had to rely on self-report measures. Thus, these results do not address questions concerning whether a transdiagnostic approach produces results comparable to disorder-specific interventions and future research may benefit from using non self-report based measures such as structured diagnostic interviews at follow-up time points. We have begun trials to explore and address both of these issues. In addition, the thresholds we used for triggering safety protocols and for determining clinically significant deterioration reflect the pragmatic requirements of this trial, and may not apply in other situations.</p></sec><sec id="s4c"><title>Conclusions</title><p>The present results indicate that self-guided transdiagnostic iPT interventions can be developed, which result in clinically significant outcomes on generic measures of anxiety and depression and are acceptable to consumers. The inclusion of automated emails facilitated adherence and completion, particularly for those with comorbid or elevated symptoms. Replication is required with samples that include those with subclinical symptoms. Direct comparisons with disorder-specific programs are also necessary to determine the benefits of the Wellbeing Course for people with specific diagnoses. Further attention to developing strategies that facilitate adherence, engagement, learning and consumer safety are likely to help realise the potential of self-guided interventions.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0062873.s001"><label>Checklist S1.</label><caption><p>
<bold>CONSORT Checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0062873.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0062873.s002"><label>Protocol S1</label><caption><p>
<bold>Trial Protocol.</bold>
</p><p>(PDF)</p></caption><media xlink:href="pone.0062873.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0062873-Kessler1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Kessler</surname><given-names>RC</given-names></name>, <name><surname>Aguilar-Gaxiola</surname><given-names>S</given-names></name>, <name><surname>Alonso</surname><given-names>J</given-names></name>, <name><surname>Chatterji</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The global burden of mental disorders: An update from the WHO World Mental Health (WMH) Surveys</article-title>. <source>Epidemiol Psichiatr Soc</source>
<volume>18</volume>: <fpage>23</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">19378696</pub-id></mixed-citation></ref><ref id="pone.0062873-Titov1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name> (<year>2011</year>) <article-title>Internet-delivered psychotherapy for depression in adults</article-title>. <source>Curr Opin Psychiatry</source>
<volume>24</volume>: <fpage>18</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">20827199</pub-id></mixed-citation></ref><ref id="pone.0062873-Andersson1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Andersson</surname><given-names>G</given-names></name>, <name><surname>Cuijpers</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Internet based and other computerized psychological treatments for adult depression: A meta-analysis</article-title>. <source>Cogn Behav Ther</source>
<volume>38</volume>: <fpage>196</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">20183695</pub-id></mixed-citation></ref><ref id="pone.0062873-Andrews1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Cuijpers</surname><given-names>P</given-names></name>, <name><surname>Craske</surname><given-names>M</given-names></name>, <name><surname>McEvoy</surname><given-names>P</given-names></name>, <name><surname>Titov</surname><given-names>N</given-names></name> (<year>2010</year>) <article-title>Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: A meta-analysis</article-title>. <source>PLoS ONE</source>
<volume>5</volume>: <fpage>e13196</fpage>.<pub-id pub-id-type="pmid">20967242</pub-id></mixed-citation></ref><ref id="pone.0062873-Cuijpers1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Cuijpers</surname><given-names>P</given-names></name>, <name><surname>Marks</surname><given-names>IM</given-names></name>, <name><surname>van Straten</surname><given-names>A</given-names></name>, <name><surname>Cavanagh</surname><given-names>K</given-names></name>, <name><surname>Gega</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Computer-aided psychotherapy for anxiety disorders: A meta-analytic review</article-title>. <source>Cogn Behav Ther</source>
<volume>38</volume>: <fpage>66</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">20183688</pub-id></mixed-citation></ref><ref id="pone.0062873-Lewis1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Lewis</surname><given-names>C</given-names></name>, <name><surname>Pearce</surname><given-names>J</given-names></name>, <name><surname>Bisson</surname><given-names>JI</given-names></name> (<year>2012</year>) <article-title>Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review</article-title>. <source>Brit J Psychiatr</source>
<volume>200</volume>: <fpage>15</fpage>&#x02013;<lpage>21</lpage>.</mixed-citation></ref><ref id="pone.0062873-Johnston1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Johnston</surname><given-names>L</given-names></name>, <name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Spence</surname><given-names>J</given-names></name>, <name><surname>Dear</surname><given-names>BF</given-names></name> (<year>2011</year>) <article-title>A randomized controlled trial of a transdiagnostic Internet-delivered treatment for anxiety disorders</article-title>. <source>PLoS ONE</source>
<volume>6</volume>: <fpage>e28079</fpage>.<pub-id pub-id-type="pmid">22132216</pub-id></mixed-citation></ref><ref id="pone.0062873-Dear1"><label>8</label><mixed-citation publication-type="other">Dear BF, Titov N, Schwencke G, Andrews G, Johnston L, <etal>et al</etal>.. (2011) An open trial of a brief transdiagnostic treatment for anxiety and depression. Behav Res Ther 49; 830&#x02013;7.</mixed-citation></ref><ref id="pone.0062873-Titov2"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Dear</surname><given-names>BF</given-names></name>, <name><surname>Schwencke</surname><given-names>G</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Johnston</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Transdiagnostic Internet treatment of anxiety and depression: A randomised controlled trial</article-title>. <source>Behav Res Ther</source>
<volume>49</volume>: <fpage>441</fpage>&#x02013;<lpage>452</lpage>.<pub-id pub-id-type="pmid">21679925</pub-id></mixed-citation></ref><ref id="pone.0062873-Klein1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Klein</surname><given-names>B</given-names></name>, <name><surname>Meyer</surname><given-names>D</given-names></name>, <name><surname>Austin</surname><given-names>D</given-names></name>, <name><surname>Kyrios</surname><given-names>M</given-names></name> (<year>2011</year>) <article-title>Anxiety Online - A Virtual Clinic: Preliminary outcomes following completion of five fully automated treatment programs for the anxiety disorders and symptoms</article-title>. <source>J Med Internet Res</source>
<volume>13</volume>: <fpage>e89</fpage>.<pub-id pub-id-type="pmid">22057287</pub-id></mixed-citation></ref><ref id="pone.0062873-Cavanagh1"><label>11</label><mixed-citation publication-type="other">Cavanagh K (2010) Turn on, tune in and (don&#x02019;t) drop out: engagement, adherence, attrition, and alliance with internet-based interventions. In Oxford Guide to Low Intensity CBT Interventions (eds: J Bennett-Levy, et al). Oxford University Press; 227&#x02013;333.</mixed-citation></ref><ref id="pone.0062873-Christensen1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Christensen</surname><given-names>H</given-names></name>, <name><surname>Griffiths</surname><given-names>KM</given-names></name>, <name><surname>Mackinnon</surname><given-names>AJ</given-names></name>, <name><surname>Brittliffe</surname><given-names>K</given-names></name> (<year>2006</year>) <article-title>Online randomized controlled trial of brief and full cognitive behaviour therapy for depression</article-title>. <source>Psychol Med</source>
<volume>36</volume>: <fpage>1737</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">16938144</pub-id></mixed-citation></ref><ref id="pone.0062873-Farvolden1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Farvolden</surname><given-names>P</given-names></name>, <name><surname>Cunningham</surname><given-names>J</given-names></name>, <name><surname>Selby</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Using e-health programs to overcome barriers to the effective treatment of mental health and addiction problems</article-title>. <source>J Technol Hum Serv</source>
<volume>27</volume>: <fpage>5</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="pone.0062873-vanDulmen1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>van Dulmen</surname><given-names>S</given-names></name>, <name><surname>Sluijs</surname><given-names>E</given-names></name>, <name><surname>van Dijk</surname><given-names>L</given-names></name>, <name><surname>de Ridder</surname><given-names>D</given-names></name>, <name><surname>Heerdink</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Patient adherence to medical treatment: a review of reviews</article-title>. <source>BMC Health Res</source>
<volume>7</volume>: <fpage>55</fpage>.</mixed-citation></ref><ref id="pone.0062873-Clarke1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Clarke</surname><given-names>C</given-names></name>, <name><surname>Eubanks</surname><given-names>D</given-names></name>, <name><surname>Reid</surname><given-names>E</given-names></name>, <name><surname>Kelleher</surname><given-names>C</given-names></name>, <name><surname>O'Connor</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Overcoming Depression on the Internet (ODIN) (2): a randomized trial of a self-help depression skills program with reminders</article-title>. <source>J Med Internet Res</source>
<volume>7</volume>: <fpage>e16</fpage>.<pub-id pub-id-type="pmid">15998607</pub-id></mixed-citation></ref><ref id="pone.0062873-Clarke2"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Clarke</surname><given-names>G</given-names></name>, <name><surname>Reid</surname><given-names>E</given-names></name>, <name><surname>Eubanks</surname><given-names>D</given-names></name>, <name><surname>O'Connor</surname><given-names>E</given-names></name>, <name><surname>DeBar</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Overcoming Depression on the Internet (ODIN): a randomized controlled trial of an Internet depression skills intervention program</article-title>. <source>J Med Internet Res</source>
<volume>4</volume>: <fpage>e14</fpage>.<pub-id pub-id-type="pmid">12554545</pub-id></mixed-citation></ref><ref id="pone.0062873-Titov3"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Choi</surname><given-names>I</given-names></name>, <name><surname>Schwencke</surname><given-names>G</given-names></name>, <name><surname>Johnston</surname><given-names>L</given-names></name> (<year>2009</year>) <article-title>Internet-based cognitive behavior therapy for social phobia without clinical input is effective: a pragmatic RCT of two types of reminders</article-title>. <source>Aust N Z J Psychiatry</source>
<volume>43</volume>: <fpage>913</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="pone.0062873-Titov4"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Schwencke</surname><given-names>G</given-names></name>, <name><surname>Robinson</surname><given-names>E</given-names></name>, <name><surname>Peters</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>An RCT of Internet CBT for social phobia with and without motivational enhancement strategies</article-title>. <source>Aust N Z J Psychiatry</source>
<volume>44</volume>: <fpage>938</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">20932208</pub-id></mixed-citation></ref><ref id="pone.0062873-Titov5"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Choi</surname><given-names>I</given-names></name>, <name><surname>Schwencke</surname><given-names>G</given-names></name>, <name><surname>Mahoney</surname><given-names>J</given-names></name> (<year>2008</year>) <article-title>Shyness 3: An RCT of guided versus unguided Internet based CBT for social phobia</article-title>. <source>Aust N Z J Psychiatry</source>
<volume>42</volume>: <fpage>1030</fpage>&#x02013;<lpage>1040</lpage>.<pub-id pub-id-type="pmid">19016091</pub-id></mixed-citation></ref><ref id="pone.0062873-Morgan1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Morgan</surname><given-names>AJ</given-names></name>, <name><surname>Jorm</surname><given-names>AF</given-names></name>, <name><surname>Mackinnon</surname><given-names>AJ</given-names></name> (<year>2012</year>) <article-title>Email-based promotion of self-help for subthreshold depression: Mood memos randomised controlled trial</article-title>. <source>Br J Psychiatry</source>
<volume>200</volume>: <fpage>412</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22442102</pub-id></mixed-citation></ref><ref id="pone.0062873-Schulz1"><label>21</label><mixed-citation publication-type="other">Schulz KF, Altman DG, Moher D, for the CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Int Med 152: Epub 24 March.</mixed-citation></ref><ref id="pone.0062873-Titov6"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Davies</surname><given-names>M</given-names></name>, <name><surname>McIntyre</surname><given-names>K</given-names></name>, <name><surname>Robinson</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Internet treatment for depression: A randomized controlled trial comparing clinician vs. technician assistance</article-title>. <source>PLoS ONE</source>
<volume>5</volume>: <fpage>e10939</fpage>.<pub-id pub-id-type="pmid">20544030</pub-id></mixed-citation></ref><ref id="pone.0062873-Robinson1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Robinson</surname><given-names>E</given-names></name>, <name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>McIntyre</surname><given-names>K</given-names></name>, <name><surname>Schwencke</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Internet treatment for generalized anxiety disorder: A randomized controlled trial comparing clinician vs. technician assistance</article-title>. <source>PLoS ONE</source>
<volume>5</volume>: <fpage>e10942</fpage>.<pub-id pub-id-type="pmid">20532167</pub-id></mixed-citation></ref><ref id="pone.0062873-Kroenke1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Kroenke</surname><given-names>K</given-names></name>, <name><surname>Spitzer</surname><given-names>RL</given-names></name>, <name><surname>Williams</surname><given-names>JBW</given-names></name> (<year>2001</year>) <article-title>The PHQ-9: Validity of a brief depression severity measure</article-title>. <source>J Gen Intern Med</source>
<volume>16</volume>: <fpage>606</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">11556941</pub-id></mixed-citation></ref><ref id="pone.0062873-Kroenke2"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Kroenke</surname><given-names>K</given-names></name>, <name><surname>Spitzer</surname><given-names>RL</given-names></name>, <name><surname>Williams</surname><given-names>JBW</given-names></name>, <name><surname>L&#x000f6;we</surname><given-names>B</given-names></name> (<year>2010</year>) <article-title>The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review</article-title>. <source>Gen Hosp Psychiatry</source>
<volume>32</volume>: <fpage>345</fpage>&#x02013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">20633738</pub-id></mixed-citation></ref><ref id="pone.0062873-Lwe1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>L&#x000f6;we</surname><given-names>B</given-names></name>, <name><surname>Decker</surname><given-names>O</given-names></name>, <name><surname>M&#x000fc;ller</surname><given-names>S</given-names></name>, <name><surname>Br&#x000e4;hler</surname><given-names>E</given-names></name>, <name><surname>Schellberg</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population</article-title>. <source>Med Care</source>
<volume>46</volume>: <fpage>266</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">18388841</pub-id></mixed-citation></ref><ref id="pone.0062873-Kroenke3"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Kroenke</surname><given-names>K</given-names></name>, <name><surname>Spitzer</surname><given-names>RL</given-names></name>, <name><surname>Williams</surname><given-names>JBW</given-names></name>, <name><surname>Monahan</surname><given-names>PO</given-names></name>, <name><surname>Lowe</surname><given-names>B</given-names></name> (<year>2007</year>) <article-title>Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection</article-title>. <source>Ann Intern Med</source>
<volume>146</volume>: <fpage>317</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">17339617</pub-id></mixed-citation></ref><ref id="pone.0062873-SeeleyWait1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Seeley-Wait</surname><given-names>E</given-names></name>, <name><surname>Abbott</surname><given-names>MJ</given-names></name>, <name><surname>Rapee</surname><given-names>RM</given-names></name> (<year>2009</year>) <article-title>Psychometric properties of the Mini-Social Phobia Inventory</article-title>. <source>Prim Care Companion J Clin Psychiatry</source>
<volume>11</volume>: <fpage>231</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">19956461</pub-id></mixed-citation></ref><ref id="pone.0062873-Stein1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Stein</surname><given-names>MB</given-names></name>, <name><surname>Roy-Byrne</surname><given-names>PP</given-names></name>, <name><surname>Mcquaid</surname><given-names>JR</given-names></name>, <name><surname>Laffaye</surname><given-names>C</given-names></name>, <name><surname>Russo</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Development of a brief diagnostic screen for panic disorder in primary care</article-title>. <source>Psychosom Med</source>
<volume>61</volume>: <fpage>359</fpage>&#x02013;<lpage>364</lpage>.<pub-id pub-id-type="pmid">10367617</pub-id></mixed-citation></ref><ref id="pone.0062873-Clark1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Clark</surname><given-names>DM</given-names></name>, <name><surname>Layard</surname><given-names>R</given-names></name>, <name><surname>Smithies</surname><given-names>R</given-names></name>, <name><surname>Richards</surname><given-names>DA</given-names></name>, <name><surname>Suckling</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Improving access to psychological therapy: Initial evaluation of two UK demonstration sites</article-title>. <source>Behav Res Ther</source>
<volume>47</volume>: <fpage>910</fpage>&#x02013;<lpage>920</lpage>.<pub-id pub-id-type="pmid">19647230</pub-id></mixed-citation></ref><ref id="pone.0062873-Richards1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Richards</surname><given-names>DA</given-names></name>, <name><surname>Suckling</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Improving access to psychological therapies: Phase IV prospective cohort study</article-title>. <source>Br J Clin Psychol</source>
<volume>48</volume>: <fpage>377</fpage>&#x02013;<lpage>396</lpage>.<pub-id pub-id-type="pmid">19208291</pub-id></mixed-citation></ref><ref id="pone.0062873-Gilbody1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Gilbody</surname><given-names>S</given-names></name>, <name><surname>Richards</surname><given-names>D</given-names></name>, <name><surname>Brealey</surname><given-names>S</given-names></name>, <name><surname>Hewitt</surname><given-names>C</given-names></name> (<year>2007</year>) <article-title>Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis</article-title>. <source>J Gen Intern Med</source>
<volume>22</volume>: <fpage>1596</fpage>&#x02013;<lpage>1602</lpage>.<pub-id pub-id-type="pmid">17874169</pub-id></mixed-citation></ref><ref id="pone.0062873-Bandura1"><label>33</label><mixed-citation publication-type="other">Bandura A (1986) Social Foundations of Thought and Action. Prentice Hall.</mixed-citation></ref><ref id="pone.0062873-Hinyard1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Hinyard</surname><given-names>LJ</given-names></name>, <name><surname>Kreuter</surname><given-names>MW</given-names></name> (<year>2007</year>) <article-title>Using narrative communication as a tool for health behavior change: A conceptual, theoretical, and empirical overview</article-title>. <source>Health Educ Behav</source>
<volume>34</volume>: <fpage>777</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">17200094</pub-id></mixed-citation></ref><ref id="pone.0062873-Chang1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>C</given-names></name> (<year>2008</year>) <article-title>Increasing mental health literacy via narrative advertising</article-title>. <source>J Health Commun</source>
<volume>13</volume>: <fpage>37</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">18307135</pub-id></mixed-citation></ref><ref id="pone.0062873-Wilson1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Wilson</surname><given-names>EJ</given-names></name>, <name><surname>Sherrell</surname><given-names>DL</given-names></name> (<year>1993</year>) <article-title>Source effects in communication and persuasion research: A meta-analysis of effect size</article-title>. <source>J Academy of Marketing Science</source>
<volume>21</volume>: <fpage>101</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="pone.0062873-Meyer1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Meyer</surname><given-names>B</given-names></name>, <name><surname>Berger</surname><given-names>T</given-names></name>, <name><surname>Caspar</surname><given-names>F</given-names></name>, <name><surname>Beevers</surname><given-names>CG</given-names></name>, <name><surname>Andersson</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial</article-title>. <source>J Med Internet Res</source>
<volume>11</volume>: <fpage>e15</fpage>.<pub-id pub-id-type="pmid">19632969</pub-id></mixed-citation></ref><ref id="pone.0062873-McEvoy1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>McEvoy</surname><given-names>PM</given-names></name>, <name><surname>Nathan</surname><given-names>P</given-names></name>, <name><surname>Norton</surname><given-names>PJ</given-names></name> (<year>2009</year>) <article-title>Efficacy of transdiagnostic treatments: A review of published outcome studies and future research directions</article-title>. <source>J Cogn Psychother</source>
<volume>23</volume>: <fpage>20</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="pone.0062873-Meyer2"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Meyer</surname><given-names>B</given-names></name>, <name><surname>Berger</surname><given-names>T</given-names></name>, <name><surname>Caspar</surname><given-names>F</given-names></name>, <name><surname>Beevers</surname><given-names>CG</given-names></name>, <name><surname>Andersson</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial</article-title>. <source>J Med Internet Res</source>
<volume>11</volume>: <fpage>e15</fpage>.<pub-id pub-id-type="pmid">19632969</pub-id></mixed-citation></ref><ref id="pone.0062873-Cuijpers2"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Cuijpers</surname><given-names>P</given-names></name>, <name><surname>Donker</surname><given-names>T</given-names></name>, <name><surname>van Straten</surname><given-names>A</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Andersson</surname><given-names>G</given-names></name> (<year>2010</year>) <article-title>Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies</article-title>. <source>Psychol Med</source>
<volume>40</volume>: <fpage>1943</fpage>&#x02013;<lpage>1957</lpage>.<pub-id pub-id-type="pmid">20406528</pub-id></mixed-citation></ref><ref id="pone.0062873-Gellatly1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Gellatly</surname><given-names>J</given-names></name>, <name><surname>Bower</surname><given-names>P</given-names></name>, <name><surname>Hennessy</surname><given-names>S</given-names></name>, <name><surname>Richards</surname><given-names>D</given-names></name>, <name><surname>Gilbody</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>What makes self-help interventions effective in the management of depressive symptoms? Meta-analysis and meta-regression</article-title>. <source>Psychol Med</source>
<volume>37</volume>: <fpage>1217</fpage>&#x02013;<lpage>1228</lpage>.<pub-id pub-id-type="pmid">17306044</pub-id></mixed-citation></ref><ref id="pone.0062873-Christensen2"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Christensen</surname><given-names>H</given-names></name>, <name><surname>Griffiths</surname><given-names>KM</given-names></name>, <name><surname>Farrer</surname><given-names>L</given-names></name> (<year>2009</year>) <article-title>Adherence in internet interventions for anxiety and depression: Systematic review</article-title>. <source>J Med Internet Res</source>
<volume>112</volume>: <fpage>e13</fpage>.</mixed-citation></ref><ref id="pone.0062873-Berger1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Berger</surname><given-names>T</given-names></name>, <name><surname>H&#x000e4;mmerli</surname><given-names>K</given-names></name>, <name><surname>Gubser</surname><given-names>N</given-names></name>, <name><surname>Andersson</surname><given-names>G</given-names></name>, <name><surname>Caspar</surname><given-names>F</given-names></name> (<year>2011</year>) <article-title>Internet-based treatment of depression: A randomized controlled trial comparing guided with unguided self-help</article-title>. <source>Cogn Behav Ther</source>
<volume>40</volume>: <fpage>2512</fpage>&#x02013;<lpage>266</lpage>.</mixed-citation></ref><ref id="pone.0062873-Furmark1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Furmark</surname><given-names>T</given-names></name>, <name><surname>Carlbring</surname><given-names>P</given-names></name>, <name><surname>Hedman</surname><given-names>E</given-names></name>, <name><surname>Sonnenstein</surname><given-names>A</given-names></name>, <name><surname>Clevberer</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Guided and unguided self-help for social anxiety disorder: randomised controlled trial</article-title>. <source>Br J Psychiatry</source>
<volume>195</volume>: <fpage>440</fpage>&#x02013;<lpage>447</lpage>.<pub-id pub-id-type="pmid">19880935</pub-id></mixed-citation></ref><ref id="pone.0062873-Titov7"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Titov</surname><given-names>N</given-names></name>, <name><surname>Andrews</surname><given-names>G</given-names></name>, <name><surname>Kemp</surname><given-names>A</given-names></name>, <name><surname>Robinson</surname><given-names>E</given-names></name> (<year>2010</year>) <article-title>Characteristics of adults with anxiety or depression treated at an Internet clinic: Comparison with a national survey and an outpatient clinic</article-title>. <source>PLoS ONE</source>
<volume>5</volume>: <fpage>e10885</fpage>.<pub-id pub-id-type="pmid">20526371</pub-id></mixed-citation></ref></ref-list></back></article>